Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Friday, March 6, 2026
Calidi’s $5 Million Public Offering
Thursday, March 5, 2026
Atavistik’s $40 Million Series B
CytoDyn’s $17 Million Private Placement
Wednesday, March 4, 2026
Teva’s $400 Million Fund Raise
MAIA’s $30 Million Public Offering
Sernova’s $20 Million Debt Financing
Can-Fite’s $4 Million Warrant Exercise
Tuesday, March 3, 2026
Prolium’s $50 Million Series A
Polares’s $50 Million Series C
Antiverse’s $9 Million Series A
Monday, March 2, 2026
Royalty’s $250 Million Royalty and Debt Financing
Palvella’s $230 Million Public Offering…More
Arcellx’s $10 Million Stock Sale
Friday, February 27, 2026
Zura’s $144 Million Public Offering
Defence’s $11 Million Private Placement
Sharp’s $500 Thousand Debt Financing
Thursday, February 26, 2026
Compass’s $200 Million Warrant Exercise
Bicara’s $172 Million Public Offering…More
Wednesday, February 25, 2026
Larimar’s $100 Million Public Offering
BreezeBio’s $60 Million Series B
Tuesday, February 24, 2026
Alveus’s $197 Million Series A
Monday, February 23, 2026
Salspera’s $85 Million IPO…More
Saturday, February 21, 2026
Eupraxia’s $63 Million Public Offering
Friday, February 20, 2026
TriSalus’s $40 Million Public Offering
Rakovina’s $1 Million Debt Financing and $1 Million Private Placement
Brainstorm’s $1 Million Private Placement
Thursday, February 19, 2026
Candel’s $100 Million Public Offering
Ten63’s $45 Million Venture Financing
Moleculin’s $8 Million Warrant Exercise
Resverlogix’s $3 Million Private Placement
Wednesday, February 18, 2026
Korsana’s $175 Million Venture Financing
Compass’s $150 Million Public Offering
ProSomnus’s $38 Million Equity Investment
Sift’s $4 Million Pre-seed Financing
Tuesday, February 17, 2026
Immunic’s $200 Million Private Placement…More
GelMEDIX’s $13 Million Seed Round
Cingulate’s $12 Million Private Placement
Q32’s $10 Million Registered Direct Offering
Resurrect’s $8 Million Series A
Mainz’s $6 Million Private Placement
Liminatus’s $4 Million Public Offering
HCW’s $1 Million Public Offering
Scinai’s Acquisition of Recipharm
Friday, February 13, 2026
Galecto’s $316 Million Public Offering…More
Newron’s $45 Million Debt Financing
Opus’s $25 Million Private Placement
OKYO’s $20 Million Public Offering
BioRestorative’s $5 Million Public Offering
Thursday, February 12, 2026
BioMarin’s $850 Million Debt Financing
Evommune’s $125 Million Private Placement
Coherus’s $50 Million Public Offering
Berlin’s $10 Million Fund Raise
Wednesday, February 11, 2026
Nektar’s $400 Million Public Offering…More
Xilio’s $75 Million Public Offering
Neurent’s $74 Million Series C
iMDx’s $26 Million Registered Direct Offering
Nasus’s $15 Million Private Placement
Biorestorative’s $5 Million Public Offering
AstraZeneca’s $3 Million Grant
Tuesday, February 10, 2026
Sutro’s $110 Million Public Offering
L-Nutra’s $84 Million Series D
Kainova’s $32 Million Series B
4Moving’s $14 Million Venture Financing
ArrayPatch’s $3 Million Seed Round
Monday, February 9, 2026
SpyGlass’s $173 Million IPO…More
Satellos’s $57 Million Public Offering
Pandorum’s $18 Million Series B
XOMA’s $5 Million Acquisition of Generation Bio
Friday, February 6, 2026
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.